Paradoxical effects of iron chelation on growth of vascular endothelial cells

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 6, 2005, Pages 539-544

  Hodges, Yvonne K ^a   Reese, Sara M ^a   Pahl, Paula M B ^a   Horwitz, Lawrence D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiogenesis; Hypoxia inducible factor (HIF); Restenosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DEFEROXAMINE; DESFERRIEXOCHELIN 772SM; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; IRON CHELATING AGENT; TRITIUM; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL HYPOXIA; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON CHELATION; PRIORITY JOURNAL; RESTENOSIS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GROWTH INHIBITORS; HUMANS; IRON CHELATING AGENTS;

EID: 19544382183     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000159659.78675.4a     Document Type: Article

References (29)

1. Clowes AW. Regulation of smooth muscle proliferation and migration. Transplant Proc. 1999;31:810-811.
2. Parikh SA, Edelman ER. Endothelial cell delivery for cardiovascular therapy. Adv Drug Deliv Rev. 2000;42:139-161.
3. Imegwu OJ, Entersz I, Graham AM, et al. Heterotypic smooth muscle cell/endothelial cell interations differ between species. J Surg Res. 2001; 98:85-88.
4. Lafont A, Durand E, Samuel JL, et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation. 1999;100:1109-1115.
5. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol. 1997; 20:3-10.
6. Pahl PM, Yan XD, Hodges YK, et al. An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem. 2000;275:17821-17826.
7. Chong TW, Horwitz LD, Moore JW, et al. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Cancer Res. 2002; 62:6924-6927.
8. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-2804.
9. Smith C, Mitchinson MJ, Aruoma OI, et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
10. Horwitz LD, Sherman NA, Kong Y, et al. Lipophilic siderphores of Mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci USA. 1998;95:5263-5268.
11. Das M, Bouchey DM, Moore MJ, et al. Hypoxia-induced proliferative response of vascular adventitial fibroblast is dependent on G protein-mediated activation of mitogen-activated protein kinases. J Biol Chem. 2001;276:15631-15640.
12. Gobin J, Moore CH, Reeve JRJ, et al. Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA. 1995;92:5189-5193.
13. Gobin J, Horwitz MA. Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Exp Med. 1996;183:1527-1532.
14. Eriksson S, Graslund A, Skog S, et al. Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. J Biol Chem. 1984; 259:11695-11700.
15. Hodges YK, Antholine WE, Horwitz LD. Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins. Biochem Biophys Res Commun. 2004;315:595-598.
16. Kunsch C, Medford RM. Oxidative stress as regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
17. Srinivas V, Zhu X, Salceda S, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha) is a non-heme iron protein. Implications for oxygen sensing. J Biol Chem. 1998;273:18019-18022.
18. Semenza GL. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med. 1998;131:207-214.
19. 2 sensing. Science. 2001;292:464-468.
20. 2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
21. Berra E, Pages G, Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 2000;19:139-145.
22. Kappel A, Ronicke V, Damert A, et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood. 1999;93:4284-4292.
23. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res. 1995;77:638-643.
24. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
25. Rosenthal EA, Bohlmeyer TJ, Monnet E, et al. An iron-binding exochelin prevents restenosis due to coronary artery balloon injury in a porcine model. Circulation. 2001;104:2222-2227.
26. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 2003; 107:777-784.
27. Horwitz LD, Kaufman D, Keller MW, et al. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. Circulation. 1994;90:2439-2447.
28. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet. 2001;357:33-37.
29. Sata M. Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation. Trends Cardiovasc Med. 2003;13: 249-253.